Drug Companies Overcharge in Europe by Billions by Blocking Generics Says EU     Print Email

European consumers and state-run health-care programs are being charged an extra €3 billion ($3.87 billion) annually because major pharmaceutical companies are creating barriers for the production and use of cheaper generic drugs, the European Commission says.

After a year-long probe into some of the leading companies’ practices, the commission said in a 400-page preliminary report that these multinationals “routinely use questionable tactics to delay market entry of generic drugs.”

While the Commission did not name names, Commission sources said that the companies included some of the world’s leading brands. EU antitrust chief Neelie Kroes warned in a news conference November 28 that “the Commission will not hesitate to open antitrust cases against companies where there are indications that the antitrust rules may have been breached.”

Tactics employed by the “originator companies” that the Commission singled out for blame include the seeking of hundreds of superfluous patents for popular medications to block generic manufactures from obtaining production rights; filing frivolous lawsuits against these manufacturers; and brokering back-room deals to keep medicines off the market for a period of time. The result was producers of generic drugs received more than €200 million in payments for keeping cheaper versions shelved.

The report’s discovery – big pharmaceutical companies are cheating on the system – will surprise people who have long admired European nations for their health-care policies aimed at keeping down cost to benefit consumers, including by the promotion of competition and the readiness to promote cheaper generics after the original patents on drugs have expired.

In 2007, European Affairs published an article in which Gretchen A. Jacobson, health economist with the Congressional Research Services, noted the price disparities between the U.S. and Western Europe for the same drugs and said that “the majority of researchers believe people in the U.S. pay more for certain pharmaceuticals than people in some western European countries.”

Noting that medication costs fall between 20 and 90 per cent after the introduction of generics, the Commission estimated that significant savings would have been possible had the medicines entered the market unabated, but this decrease in price provides incentives for pharmaceutical companies to maintain a stranglehold on production rights.

There is a widely held view European policies aimed at keeping drug prices low have had the long-term effect of driving cutting-edge medical research, development and innovation to the United States.

 
  • High Skills versus Family-Based Immigration Policy: Complex Considerations.

    By Nicholas Zill

    In the current era of rapid demographic and technological change, and massive refugee flows, there has been much debate in European nations and in the US about immigration policies. One of the major points of contention is whether preferences should be given to would-be entrants on the basis of their high skills (merit-based immigration) or their family ties to individuals already residing in the country (family reunification).

    Read more ...

UMD Jean Monnet Research Project

Infrastructure Planning and Financing: Lessons from Europe and the United States

The University of Maryland has received a Jean Monnet grant from the EU to conduct a series of policy exchanges between Europe and the US on filling infrastructure needs and the utility of public/private partnerships as the financing mechanism. If interested in participating in or receiving more information about these exchanges, please contact Rye McKenzie (rmckenzi@umd.edu).

Read more ...

New from the Bertelsmann Foundation

The Bertelsmann Foundation is an independent, nonpartisan and nonprofit think tank in Washington, DC with a transatlantic perspective on global challenges.

"Edge of a Precipice" by Nathan Crist

"Newpolitik" by Emily Hruban

 

Summer Course